Clinical Trials Directory

Trials / Unknown

UnknownNCT03379896

Study on Antigen-presenting Function of Gamma Delta T Cells in Sepsis and Its Molecular Mechanisms

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
West China Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Study on antigen-presenting function of gamma delta T cells in sepsis and its molecular mechanisms

Detailed description

The latest definition of sepsis highlights the role of dysregulated host response to infection in organ dysfunction aggravation. Maintenance of immune homeostasis of septic patients through immunotherapy is the key breakthrough to improve success rate. Antigen-presenting cell (APC) is the bridge that connects the innate and adaptive immunity. Decrease of count and function of APC has been shown to be associated with worsened clinical outcomes in patients with sepsis. Gamma-delta T cells (γδ T cells) are the newly identified population of T lymphocytes. Recent studies have found that γδ T cells possess unique and powerful antigen-presenting function, making them the hot topic in infection and cancer research. Based on the results, the investigator plan to evaluate the antigen-presenting function changes of γδ T cells in septic status by analyzing the antigen-presenting related molecules on γδ T cells, antigen protein uptake ability, and their function on the proliferation and activation of CD8+ T lymphocytes. Furthermore, the investigator will explore the mechanism and signal pathways for the APC function changes of γδ T cells. Findings from this research could help explain the mechanism of sepsis induced immune dysfunction, enrich our understanding of the important role of γδ T cells, and build a good foundation for immunotherapy in sepsis.

Conditions

Interventions

TypeNameDescription
OTHERCollect peripheral blood sampleCollect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.

Timeline

Start date
2018-01-04
Primary completion
2020-06-30
Completion
2020-12-30
First posted
2017-12-20
Last updated
2017-12-22

Source: ClinicalTrials.gov record NCT03379896. Inclusion in this directory is not an endorsement.